Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Without published details on the animal study design, sample sizes, dosing protocols, and statistical analyses, it is difficult to assess the robustness of these findings
What are the long-term effects and safety profiles of metabolic interventions targeting amino acids in IPF patients
The GLO1 C332 (Ala111) allele confers autism vulnerability
Recurrent probabilistic neural network-based short-term prediction for acute hypotension and ventricular fibrillation
REDEFINE-1: Phase 3 Pivotal Trial (NCT05064293) Study Title: "Efficacy and Safety of CagriSema in Adults With Overweight or Obesity (REDEFINE 1)" Status: Completed (Results Published 2024) Phase: Phase 3 Enrollment: 3,400+ participants Study Period: 2021-2024 Location: Global, 15+ countries Design: Randomized, double-blind, active-controlled Duration: 68 weeks Intervention: CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) vs
US$ 23.32
US$ 27.87
US$ 25.24
US$ 20.91
